Syndicate content

Researchers Find a Possible New Treatment for Aggressive Triple-Receptor-Negative Breast Cancer; New Inhibitor of Cancer Stem-Like Cells Brings New Hope

Scientists from the cluster of excellence BIOSS Centre for Biological Signaling Studies at the University of Freiburg and the Freiburg University Medical Center in Germany have shown that inhibiting the epigenetic regulator KDM4 might offer a potential novel treatment option for breast cancer patients. They used a newly established cell model that enables scientists to isolate cancer stem cells directly from patient tumor. Using this special culture system, they were able to test potential new cancer drugs. One of these, a novel inhibitor of the epigenetic regulator KDM4, co-developed in the lab of Professor Roland Schüle, showed promising results. The researchers published their work online on September 7, 2017 in Cancer Research. The article is titled “KDM4 Inhibition Targets Breast Cancer Stem-Like Cells.” Although the prognosis for breast cancer has been steadily improving in the last decades, patients with triple-receptor-negative breast cancer form a subgroup who receive a considerably worse prognosis in most cases. Roughly 15 percent of all breast cancer patients have triple-receptor-negative breast cancer, which lacks markers for a targeted therapy. In the last few years, a bulk of data pointing to a small population of cells in tumors that maintain tumor growth, are particularly resistant to chemotherapy, are responsible for relapses, and develop metastases. These cells, named cancer stem-like cells, share many characteristics with the body’s normal stem cells. Due to their cancer-driving behavior, researchers have been focusing more and more on targeting these cells. However, there are currently only a few models available to study the biology of cancer stem cells. Scientists from the University of Freiburg's new Center for Translational Cell Research have developed a model that allows scientists to isolate cancer stem cells from tumors obtained from breast cancer patients, thereby making biochemical and molecular analysis much more feasible. Dr. Jochen Maurer and his research group were able to cultivate several cancer stem cell lines from triple-receptor-negative breast cancer that are excellent representations of the original tumors they isolated from the patients.

In collaboration with Prof. Dr. Schüle and his team at the Center of Clinical Research of the Freiburg University Medical Center, the scientists were able to test several epigenetic inhibitors that had been newly developed by Dr. Schüle and his team on the cancer stem cell model. Epigenetics relates to the regulation of genes without involving changes in the DNA sequence and is regarded as one of the most important issues of the 21st century. It is believed that epigenetics play a huge role in the development and progression of cancer.

Dr. Schüle and his team have already conducted well-known studies on the epigenetic regulator LSD1. Now, they have discovered that an inhibitor of the epigenetic regulator KDM4 shows great promise in modulating breast cancer stem cell pathology. They were able to block proliferation of several cancer stem cell lines. In addition, the KDM4 inhibitor induces a change of the molecular make-up of the cancer stem cells and drives them out of stem-ness. Finally, they were also able to reduce tumor growth in their first in vivo xenograft analysis.

IMAGE

Image shows breast cancer stem cell line 1 (BCSC1) from the newly established cell model. Here we can see the proteins keratin 5 in green and keratin 8 in red, with the nucleus in blue. (Source: Maurer Lab).

[Press release] [Cancer Researchn abstract]